pharmaphorum June 14, 2024
The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammatory bowel disease (IBD) therapy still in preclinical development.
AbbVie is paying $150 million upfront for rights to Chinese biotech FutureGen Biopharmaceutical’s FG-M701, described as a next-generation antibody that binds to tumour necrosis factor-like ligand 1A (TL1A), which has emerged as a popular new target in IBD with several candidates in a race to market.
According to AbbVie, FG-M701 could offer best-in-class functional characteristics compared to what it calls first-generation TL1A antibodies, with the potential to offer “greater efficacy and less frequent dosing as a therapy for IBD,” which includes...
Today's Sponsors
Today's Sponsor